Last reviewed · How we verify

Daprodustat (GSK1278863)

GlaxoSmithKline · Phase 3 active Small molecule

Daprodustat (GSK1278863) is a HIF prolyl hydroxylase inhibitor Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Anemia of chronic kidney disease, Anemia in patients with chronic kidney disease not on dialysis.

Daprodustat inhibits hypoxia-inducible factor prolyl hydroxylase (HIF-PH), stabilizing HIF and increasing endogenous erythropoietin production to treat anemia.

Daprodustat inhibits hypoxia-inducible factor prolyl hydroxylase (HIF-PH), stabilizing HIF and increasing endogenous erythropoietin production to treat anemia. Used for Anemia of chronic kidney disease, Anemia in patients with chronic kidney disease not on dialysis.

At a glance

Generic nameDaprodustat (GSK1278863)
SponsorGlaxoSmithKline
Drug classHIF prolyl hydroxylase inhibitor
TargetProlyl hydroxylase domain-containing proteins (PHD)
ModalitySmall molecule
Therapeutic areaHematology
PhasePhase 3

Mechanism of action

By inhibiting prolyl hydroxylase domain-containing proteins (PHD enzymes), daprodustat prevents the degradation of hypoxia-inducible factor (HIF), allowing HIF to accumulate and activate genes involved in erythropoiesis. This leads to increased endogenous erythropoietin (EPO) production and improved red blood cell formation, addressing anemia without requiring exogenous EPO administration. The mechanism mimics the body's natural hypoxic response to low oxygen levels.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Daprodustat (GSK1278863)

What is Daprodustat (GSK1278863)?

Daprodustat (GSK1278863) is a HIF prolyl hydroxylase inhibitor drug developed by GlaxoSmithKline, indicated for Anemia of chronic kidney disease, Anemia in patients with chronic kidney disease not on dialysis.

How does Daprodustat (GSK1278863) work?

Daprodustat inhibits hypoxia-inducible factor prolyl hydroxylase (HIF-PH), stabilizing HIF and increasing endogenous erythropoietin production to treat anemia.

What is Daprodustat (GSK1278863) used for?

Daprodustat (GSK1278863) is indicated for Anemia of chronic kidney disease, Anemia in patients with chronic kidney disease not on dialysis.

Who makes Daprodustat (GSK1278863)?

Daprodustat (GSK1278863) is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What drug class is Daprodustat (GSK1278863) in?

Daprodustat (GSK1278863) belongs to the HIF prolyl hydroxylase inhibitor class. See all HIF prolyl hydroxylase inhibitor drugs at /class/hif-prolyl-hydroxylase-inhibitor.

What development phase is Daprodustat (GSK1278863) in?

Daprodustat (GSK1278863) is in Phase 3.

What are the side effects of Daprodustat (GSK1278863)?

Common side effects of Daprodustat (GSK1278863) include Hypertension, Headache, Diarrhea, Nausea, Thrombotic events.

What does Daprodustat (GSK1278863) target?

Daprodustat (GSK1278863) targets Prolyl hydroxylase domain-containing proteins (PHD) and is a HIF prolyl hydroxylase inhibitor.

Related